Back to Awarded Treatment Trials


Awarded Trial: 02T-119

Grant ID

02T-119

Illness

Schizophrenia

Primary Drug/Intervention

Amridin

Primary Dosage

60-120mg

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Morozova

Sample Size

60

Duration of Study Period for Each Subject

10 months

Outcome Measurements

Cognitive battery, PANSS, CGI

Results

Amridin is a reversible cholinesterase inhibitor, muscarinic M1 + M3 antagonist and M2 partial agonist. At higher doses the drug also inhibits MAO-B. Patients who had been receiving risperidone therapy for at least 4 weeks, were randomized to receive amridin or placebo as adjunctive therapy in a 2:1 ratio. There were subtle but significant benefits for amiridin on PANSS positive, PANSS negative, CGI and several cognitive tests.

Publication

N/A

Link

N/A

PI Name

Margarita Morozova

Degree

MD

Center

Mental Health Research Center

Institution

Russian Academy of Medical Sciences

Address

Zagorodnoe Shosse 2, korp. 2

City or Town

Moscow

State or Province

N/A

Zip or Postal Code

113152

Country

Russia

Email Address

m_morozova01@mail.ru